ArticleEuropean journal of nuclear medicine and molecular imaging2022
Fibroblast activation protein imaging in reperfused ST-elevation myocardial infarction: comparison with cardiac magnetic resonance imaging.
Article in European journal of nuclear medicine and molecular imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 64 citations in OpenAlex.
- Non-invasive imaging in heart transplant recipients: state of art and future direction.European journal of nuclear medicine and molecular imaging · 2026Review
- Early post-infarct fibroblast activation protein-targeted PET/CT withEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Coronary artery disease imaging with total-body PET.The British journal of radiology · 2026Review
- Comparison of the distribution and functional significance of myocardial fibroblast activation and inflammation in reperfused ST-elevation myocardial infarction.Quantitative imaging in medicine and surgery · 2026Article
- Fibroblast Activation Protein Inhibitor (FAPI) PET: A Scoping Review of Emerging Oncologic and Fibroinflammatory Applications.Diagnostics (Basel, Switzerland) · 2026Review
- FAPi-PET/CT as surrogate marker for subclinical myocardial fibrosis is a prognostic tool for patients undergoing left-sided heart valve surgery.EJNMMI research · 2026Article
- Cardio-Vascular Extracellular Matrix: The Unmet Enigma.International journal of molecular sciences · 2026Review
- How Rapidly Does the FAPI PET Signal Reverse Following Therapy? Assessing the FAPI PET Signal in Hypertensive Cardiac Injury and Fibrosis in Mice.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Total-body positron emission tomography: Investigating mechanisms in cardiovascular-kidney-metabolic syndrome.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2025Review
- Evaluation of myocardial fibrosis and wall motion abnormality withEJNMMI research · 2025Article
- Application ofMedComm · 2025Article
- Fibroblast Activation Protein Inhibitor (FAPI)-Based Theranostics.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Gallium-Labeled PET Radiopharmaceuticals in Cardiovascular Disease.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Comparison of the value of FAPI imaging and speckle‑tracking echocardiography in assessment of right ventricular remodeling in pulmonary hypertension.BMC medical imaging · 2025Article
- Imaging Fibroblast Activation Protein: Direct Visualization of Matrix Proteolytic Activity in Patients Post Myocardial Infarction.Journal of the American College of Cardiology · 2025Article
- PET-CT Imaging in Hypertrophic Cardiomyopathy: A Narrative Review on Risk Stratification and Prognosis.Diagnostics (Basel, Switzerland) · 2025Review
- Targeting fibroblast activation protein in rheumatoid arthritis: from molecular imaging to precision therapeutics.Frontiers in immunology · 2025Review
- Clinical applications of fibroblast activation protein inhibitor positron emission tomography (FAPI-PET).Npj imaging · 2024Review
- Myocardial work by pressure-strain loop is associated with molecular imaging of fibroblast activation in hypertensive hearts usingThe international journal of cardiovascular imaging · 2024Article
- Comparison of Cardiac Activated Fibroblast Imaging and Magnetic Resonance Imaging in Patients with COVID-19-Related Myocarditis.Reviews in cardiovascular medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of this study was to explore the correlation of
methodsFourteen first-time STEMI patients (11 men, mean age: 62 ± 11 years) after PPCI and 14 gender-matched healthy volunteers (10 men, mean age: 50 ± 14 years) who had completed FAPI imaging and blood sample collection were prospectively recruited. All patients underwent baseline FAPI imaging (6 ± 2 days post-MI) and CMR (8 ± 2 days post-MI). Ten patients had follow-up CMR (84 ± 4 days post-MI). Myocardial FAPI activity was analyzed for extent (the percentage of FAPI uptake volume over the left ventricular volume, FAPI%), intensity (target-to-background uptake ratio, TBRmax), and amount (FAPI% × TBRmax). Late gadolinium enhancement (LGE), T2-weighted imaging (T2WI), extracellular volume (ECV), microvascular obstruction (MVO), and cardiac function from CMR imaging were analyzed. Blood samples obtained on the day of FAPI imaging were used to assess circulating FAP, TGF-β1, TNF-α, IL-6, and hsCRP in STEMI patients and controls.
resultsLocalized but inhomogeneous FAPI uptake was observed in STEMI patients, which was larger than the edematous and infarcted myocardium, whereas no uptake was detected in controls. The MVO area showed lower FAPI uptake compared with the surrounding myocardium. FAPI activity was associated with the myocardial injury biomarkers T2WI, LGE, and ECV at both per-patient and per-segment levels (all p < 0.05), but was not associated with circulating FAP, TGF-β1, TNF-α, IL-6, or hsCRP. Among the CMR parameters, T2WI had the greatest correlation coefficient with both FAPI% and FAPI% × TBRmax. Baseline TBRmax was inversely correlated with the follow-up left ventricular ejection fraction (LVEF) (r = - 0.73, p = 0.02).
conclusionFAPI imaging detects more involved myocardium than CMR in reperfused STEMI, and is associated with myocardial damage and follow-up LVEF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.